1. **NAME OF THE MEDICINAL PRODUCT**

*Cofact 250 IU*, powder and solvent for solution for injection.

*Cofact 500 IU*, powder and solvent for solution for injection.

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**

*Cofact* (concentrate of 4 coagulation factors) is presented as a powder and solvent for solution for injection containing human prothrombin complex. The product nominally contains the following IU of the human coagulation factors tabled below:

<table>
<thead>
<tr>
<th>Component</th>
<th>Cofact 250 IU (factor IX)</th>
<th>Cofact 500 IU (factor IX)</th>
<th>After reconstitution (IU/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coagulation factor II</td>
<td>140 – 350</td>
<td>280 – 700</td>
<td>14 – 35</td>
</tr>
<tr>
<td>Coagulation factor VII</td>
<td>70 – 200</td>
<td>140 – 400</td>
<td>7 – 20</td>
</tr>
<tr>
<td>Coagulation factor IX</td>
<td>250</td>
<td>500</td>
<td>25</td>
</tr>
<tr>
<td>Coagulation factor X</td>
<td>140 – 350</td>
<td>280 – 700</td>
<td>14 – 35</td>
</tr>
</tbody>
</table>

Other Components

- Protein C: 111 – 390 IU/ml (Cofact 250 IU) or 222 – 780 IU/ml (Cofact 500 IU)
- Protein S: 10 – 80 IU/ml (Cofact 250 IU) or 20 – 160 IU/ml (Cofact 500 IU)

The total protein content per vial is 130 – 350 mg (Cofact 250 IU) or 260 – 700 mg (Cofact 500 IU). The specific activity of the product is ≥ 0.6 IU/mg, expressed as factor IX activity.

This medicinal product contains 125 - 195 mmol/l sodium per dose. To be taken into consideration by patients on a controlled diet.

For a full list of excipients, see section 6.1.

3. **PHARMACEUTICAL FORM**

Powder and solvent for solution for injection.

The powder is of bluish colour.

4. **CLINICAL PARTICULARS**

4.1 **Therapeutic indications**

- Treatment of bleeding and perioperative prophylaxis of bleeding in acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with vitamin K antagonists, or in case of overdose of vitamin K antagonists, when rapid correction of the deficiency is required.
- Treatment of bleeding and perioperative prophylaxis in congenital deficiency of any of the vitamin K dependent coagulation factors when purified specific coagulation product is not available.

4.2 **Posology and method of administration**

Posology

Only general dosage guidelines are given below. Treatment should be initiated under the supervision of a physician experienced in the treatment of coagulation disorders. The dosage and duration of the
substitution therapy depend on the severity of the disorder, on the location and extent of bleeding and on the patient’s clinical condition.

The amount and the frequency of administration should be calculated on an individual patient basis. Dosage intervals must be adapted to the different circulating half-life of the different coagulation factors in the prothrombin complex (see section 5.2). Individual dosage requirements can only be identified on the basis of regular determinations of the individual plasma levels of the coagulation factors of interest, or on global tests of the prothrombin complex levels (prothrombin time, INR), and continuous monitoring of the clinical condition of the patient.

In case of major surgical interventions precise monitoring of the substitution therapy by means of coagulation assays is essential (specific coagulation factor assays and/or global tests for prothrombin complex levels).

**Bleeding and perioperative prophylaxis of bleeding during vitamin K antagonist treatment:**

The dose will depend on the INR before treatment, the targeted INR and body weight. In the following tables approximate doses required for correction of INR at different initial INR levels are given.

The dose tables represent general dosage guidelines only which cannot replace the individual assessment of dose for every single patient and a close monitoring of INR and other coagulation parameters during therapy.

**Recommended dosages of Cofact in ml to achieve a Target INR ≤ 2.1**

<table>
<thead>
<tr>
<th>Initial INR</th>
<th>7.5</th>
<th>5.9</th>
<th>4.8</th>
<th>4.2</th>
<th>3.6</th>
<th>3.3</th>
<th>3.0</th>
<th>2.8</th>
<th>2.6</th>
<th>2.5</th>
<th>2.3</th>
<th>2.2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50 kg</td>
<td>40</td>
<td>40</td>
<td>30</td>
<td>30</td>
<td>20</td>
<td>20</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>60 kg</td>
<td>50</td>
<td>50</td>
<td>40</td>
<td>40</td>
<td>30</td>
<td>30</td>
<td>20</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>70 kg</td>
<td>60</td>
<td>50</td>
<td>50</td>
<td>40</td>
<td>40</td>
<td>30</td>
<td>30</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>80 kg</td>
<td>60</td>
<td>60</td>
<td>50</td>
<td>50</td>
<td>40</td>
<td>40</td>
<td>30</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>90 kg</td>
<td>60</td>
<td>60</td>
<td>60</td>
<td>50</td>
<td>40</td>
<td>40</td>
<td>30</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>100 kg</td>
<td>60</td>
<td>60</td>
<td>60</td>
<td>60</td>
<td>50</td>
<td>40</td>
<td>30</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>

**Recommended dosages of Cofact in ml to achieve a Target INR ≤ 1.5**

<table>
<thead>
<tr>
<th>Initial INR</th>
<th>7.5</th>
<th>5.9</th>
<th>4.8</th>
<th>4.2</th>
<th>3.6</th>
<th>3.3</th>
<th>3.0</th>
<th>2.8</th>
<th>2.6</th>
<th>2.5</th>
<th>2.3</th>
<th>2.2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50 kg</td>
<td>60</td>
<td>60</td>
<td>60</td>
<td>50</td>
<td>50</td>
<td>50</td>
<td>50</td>
<td>40</td>
<td>40</td>
<td>30</td>
<td>30</td>
<td>30</td>
</tr>
<tr>
<td>60 kg</td>
<td>80</td>
<td>70</td>
<td>70</td>
<td>60</td>
<td>60</td>
<td>60</td>
<td>50</td>
<td>50</td>
<td>40</td>
<td>40</td>
<td>40</td>
<td>30</td>
</tr>
<tr>
<td>70 kg</td>
<td>90</td>
<td>80</td>
<td>80</td>
<td>70</td>
<td>70</td>
<td>70</td>
<td>70</td>
<td>60</td>
<td>60</td>
<td>60</td>
<td>60</td>
<td>40</td>
</tr>
<tr>
<td>80 kg</td>
<td>100</td>
<td>100</td>
<td>90</td>
<td>90</td>
<td>90</td>
<td>90</td>
<td>90</td>
<td>80</td>
<td>80</td>
<td>80</td>
<td>80</td>
<td>40</td>
</tr>
<tr>
<td>90 kg</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>90</td>
<td>90</td>
<td>90</td>
<td>90</td>
<td>80</td>
<td>80</td>
<td>80</td>
<td>80</td>
<td>60</td>
</tr>
<tr>
<td>100 kg</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>90</td>
<td>90</td>
<td>90</td>
<td>80</td>
<td>80</td>
<td>80</td>
<td>80</td>
<td>60</td>
</tr>
</tbody>
</table>

The dosages are calculated based on the factor IX concentration in Cofact, because of its relatively short half-life and low yield after infusion in comparison with the other coagulation factors in PCC. It is assumed that a mean plasma concentration of factor IX ≥ 30% is sufficient to attain an INR of ≤ 2.1 and ≥ 60% to attain an INR of ≤ 1.5. Calculated amounts are rounded off on multiples of 10 ml and an upper limit of 60 or 100 ml in total was set (see tables above). The target INR values are recommended by the Federation of Dutch Thrombosis Services and are of the same order as English and German recommendations.

The correction of the vitamin K antagonist induced impairment of haemostasis persists for approximately 6-8 hours. However, the effects of vitamin K, if administered simultaneously, are usually achieved within
4-6 hours. Thus, repeated treatment with human prothrombin complex is not usually required when vitamin K has been administered.

As these recommendations are empirical and recovery and the duration of effect may vary, monitoring of INR during treatment is mandatory.

**Bleeding and perioperative prophylaxis in congenital deficiency of any of the vitamin K dependent coagulation factors when specific coagulation factor product is not available:**

The calculated required dosage for treatment is based on the empirical finding that approximately 1 IU of factor VII or factor IX per kg body weight raises the plasma factor VII or IX activity, respectively, by 0.01 IU/ml, 1 IU of factor II or X per kg body weight raises the plasma factor II or X activity by 0.02 and 0.017 IU/ml, respectively.

The dose of a specific factor administered is expressed in International Units (IU), which are related to the current WHO standard for each factor. The activity in plasma of a specific coagulation factor is expressed either as a percentage (relative to normal plasma) or in International Units (relative to the international standard for the specific coagulation factor).

One International Unit (IU) of a coagulation factor activity is equivalent to the quantity in one ml of normal human plasma.

For example, the calculation of the required dosage of factor X is based on the empirical finding that 1 International Unit (IU) of factor X per kg body weight raises the plasma factor X activity by 0.017 IU/ml. The required dosage is determined using the following formula:

\[
\text{Required units} = \text{body weight (kg)} \times \text{desired factor X rise (IU/ml)} \times 60
\]

Where 60 (ml/kg) is the reciprocal of the estimated recovery.

**Method of administration**

For instructions on reconstitution of the medicinal product before administration, see section 6.6. Cofact should be administered intravenously.

It is recommended to administer the reconstituted product at a rate of approximately 2 ml per minute.

### 4.3 Contraindications

Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

### 4.4 Special warnings and precautions for use

The advice of a specialist experienced in the management of coagulation disorders should be sought.

In patients with acquired deficiency of the vitamin K dependent coagulation factors (e.g. as induced by treatment of vitamin K antagonists), Cofact should only be used when rapid correction of the prothrombin complex levels is necessary, such as major bleeding or emergency surgery. In other cases, reduction of the dose of the vitamin K antagonist and/or administration of vitamin K is usually sufficient.

Patients receiving vitamin K antagonists may have an underlying hypercoaguable state and infusion of human prothrombin complex may exacerbate this.

In congenital deficiency of any of the vitamin K dependent factors, specific coagulation factor product should be used when available.

If allergic or anaphylactic-type reactions occur, the injection/infusion should be stopped immediately. In case of shock, standard medical treatment for shock should be implemented.

Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pools for specific
markers of infection and the inclusion of effective manufacturing steps for the inactivation/removal of viruses. Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens.

The measures taken are considered effective for enveloped viruses such as HIV, HBV, HCV and for non-enveloped virus HAV. The measures taken may be of limited value against other non-enveloped viruses such as Parvovirus B19. Parvovirus B19 infection may be serious for pregnant women (fetal infection) and for individuals with immunodeficiency or increased erythropoiesis (e.g. haemolytic anaemia).

Appropriate vaccination (hepatits A and B) should be considered for patients in regular/repeated receipt of human plasma-derived prothrombin complex products.

It is strongly recommended that every time that Cofact is administered to a patient, the name and batch number of the product are recorded in order to maintain a link between the patient and the batch of the product.

There is a risk of thrombosis or disseminated intravascular coagulation when patients, with either congenital or acquired deficiency are treated with human prothrombin complex particularly with repeated dosing. The risk may be higher in treatment of isolated factor VII deficiency, since the other vitamin K dependent coagulation factors, with longer half-lives, may accumulate to levels considerably higher than normal.

Patients given human prothrombin complex should be observed closely for signs or symptoms of intravascular coagulation or thrombosis. Because of the risk of thrombo-embolic complications, close monitoring should be exercised when administering human prothrombin complex to patients with a history of coronary heart disease, to patients with liver disease, to per- or post-operative patients, to neonates or to patients at risk of thrombo-embolic events or disseminated intravascular coagulation. In each of these situations, the potential benefit of treatment should be weighed against the risks of these complications.

No data are available regarding the use of Cofact in case of perinatal bleeding due to vitamin K deficiency in the newborn.

4.5 Interactions with other medicinal products and other forms of interactions

Human prothrombin complex products neutralise the effect of vitamin K antagonist treatment, but no interactions with other medicinal products are known.

4.6 Fertility, pregnancy and lactation

The safety of human prothrombin complex for use in human pregnancy and during lactation has not been established.

Animal studies are not suitable to assess the safety with respect to pregnancy, embryonal/foetal development, parturition or postnatal development. Therefore, human prothrombin complex should be used during pregnancy and lactation only if clearly indicated.

4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed.
4.8 Undesirable effects

Immune system disorders:
Replacement therapy may rarely lead to the formation of circulating antibodies inhibiting one or more of the human prothrombin complex factors. If such inhibition occurs, the condition will manifest itself as a poor clinical response.
Allergic or anaphylactic-type reactions have been very rarely observed.

General disorders and administration site conditions:
Increase in body temperatures has not been observed.

Vascular disorders:
There is a risk of thromboembolic episodes following the administration of human prothrombin complex (see section 4.4).
For safety with respect to transmissible agents, see 4.4.

Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the ‘Nederlands Bijwerkingen Centrum Lareb (Website: www.lareb.nl)’.

4.9 Overdose
The use of high doses of human prothrombin complex products has been associated with instances of myocardial infarction, disseminated intravascular coagulation, venous thrombosis and pulmonary embolism. Therefore, in the case of overdose, the risk of development of thrombo-embolic complications or disseminated intravascular coagulation is enhanced.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties
Pharmacotherapeutic group: antihemorrhagics, blood coagulation factors IX, II, VII and X in combination, ATC code: B02BD01
The coagulation factors II, VII, IX and X, which are synthesised in the liver with the help of vitamin K, are commonly called the Prothrombin Complex.
Factor VII is the zymogen of the active serine protease factor VIIa by which the extrinsic pathway of blood coagulation is initiated. The tissue factor-factor VIIa complex activates coagulation factors X and IX, whereby factor IXa and Xa are formed. With further activation of the coagulation cascade prothrombin (factor II) is activated and transformed to thrombin. By the action of thrombin, fibrinogen is converted to fibrin, which results in clot formation. The normal generation of thrombin is also of vital importance for platelet function as a part of the primary haemostasis.
Isolated severe deficiency of factor VII leads to reduced thrombin formation and a bleeding tendency due to impaired fibrin formation and impaired primary haemostasis. Isolated deficiency of factor IX is one of the classical haemophilia (haemophilia B). Isolated deficiency of factor II or factor X is very rare but in severe form they cause a bleeding tendency similar to that seen in classical haemophilia.
Acquired deficiency of the vitamin K dependent coagulation factors occurs during treatment with vitamin K antagonists. If the deficiency becomes severe, a severe bleeding tendency results,
characterised by retroperitoneal or cerebral bleeds rather than muscle and joint haemorrhage. Severe hepatic insufficiency also results in markedly reduced levels of the vitamin K dependent coagulation factors and a clinical bleeding tendency which, however, is often complex due to a simultaneous ongoing low-grade intravascular coagulation, low platelet levels, deficiency of coagulation inhibitors and disturbed fibrinolysis.

The administration of human prothrombin complex provides an increase in plasma levels of the vitamin K dependent coagulation factors, and can temporarily correct the coagulation defect of patients with deficiency of one or several of these factors.

5.2 Pharmacokinetic properties
Cofact is intended for intravenous administration.

The following half-life information on the four coagulation factors that are present in Cofact is described in the literature:

<table>
<thead>
<tr>
<th>Coagulation factor</th>
<th>Half-life</th>
</tr>
</thead>
<tbody>
<tr>
<td>Factor II</td>
<td>40 - 60 hours</td>
</tr>
<tr>
<td>Factor VII</td>
<td>4 - 6 hours</td>
</tr>
<tr>
<td>Factor IX</td>
<td>18 - 25 hours</td>
</tr>
<tr>
<td>Factor X</td>
<td>30 - 60 hours</td>
</tr>
</tbody>
</table>

5.3 Preclinical safety data
No experimental animal studies have been carried out with Cofact apart from one study on rats into a possible hypotensive effect (which proved not to be present).

Toxicology studies have been carried out on experimental animals with TNBP and Tween 80. Cofact contains not more than 0.4 µg TNBP per IU of factor IX and not more than 4 µg Tween 80 per IU of factor IX. When Cofact is used at the recommended dose the amounts of TNBP and Tween 80 which a patient receives, remain well below the levels which proved harmful in animal experiments.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients
Powder: trisodiumcitrate-dihydrate, sodium chloride, antithrombin ≤0.6 IU/ml.
Solvent: water for injections.

6.2 Incompatibilities
This medicinal product must not be mixed with other medicinal products.
Cofact is compatible with polypropylene material. Treatment failure can occur as a consequence of coagulation factor adsorption to the internal surface of other injection/infusion equipment.

6.3 Shelf life
3 years.
After reconstitution Cofact can be kept for 3 hours at 15-25°C before use.

6.4 Special precautions for storage
Store in a refrigerator (2°C - 8°C). Do not freeze.
Keep the vial in the outer carton in order to protect from light.
For storage conditions after reconstitution of the medicinal product, see section 6.3.

6.5 Nature and contents of container
250 IU of powder in a vial (type I glass) with a stopper (bromobutyl) + 10 ml of solvent in a vial (type I glass) with a stopper (bromobutyl) with a transfer needle and a disinfecting swab – pack size of 1.
500 IU of powder in a vial (type II glass) with a stopper (bromobutyl) + 20 ml of solvent in a vial (type I glass) with a stopper (chlorobutyl with Fluro Tec coating) with a transfer needle and a disinfecting swab – pack size of one.

6.6 Special precautions for disposal and other handling

Dissolving
The dried protein fraction should be dissolved in the prescribed volume of water for injections. If stored at 2-8 °C it is necessary to bring the vials of Cofact and the water for injections to room temperature (15-25 °C) before dissolving the preparation.

Procedure using a transfer needle
1. Remove the plastic protective cap of both the vial containing the water for injections and the vial containing the product.
2. Disinfect the rubber stoppers of both vials with the disinfecting tissue or a piece of gauze soaked in alcohol (70%).
3. Remove the protective cover from one end of the transfer needle and insert the needle into the vial containing the water for injections. Then remove the protective cover from the other end of the transfer needle, turn the vial containing the transfer needle upside down and immediately insert the needle that is still free into the vial containing product.
4. The underpressure in the vial containing product will cause the water for injections to be sucked into the vial. Recommendation: while the water for injections is flowing across, the vial containing product should be kept tilted and the water allowed to flow along the wall of the vial. This helps to dissolve the product more quickly. As soon as all the water has flowed across, the emptied vial and the transfer needle should be removed in a single action.

In order to accelerate the dissolution process the vial may be gently swirled and, if necessary, heated to 30 °C. The vial should never be shaken nor should the temperature be allowed to exceed 37 °C. If the vial is heated in a water bath, care should be taken to ensure that the water does not come into contact with the protective cap and/or the rubber stopper.

As a rule, the dried substance should be fully dissolved within 10 minutes to form a blue-coloured solution; the blue colour is caused by the presence of the plasma protein ceruloplasmin.

The solution should be clear or slightly opalescent. Do not use solutions that are cloudy or have deposits. Reconstituted product should be inspected visually for particulate matter and discoloration prior to administration.

Any unused product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER
Sanquin Plasma Products B.V.
Plesmanlaan 125
8. MARKETING AUTHORISATION NUMBER(S)
RVG 17060

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
The Netherlands: 1 October 1997/ 24 September 2011

10. DATE OF REVISION OF THE TEXT
5 September 2016